Apellis Pharmaceuticals announced preliminary U.S. net product revenues for full-year 2025 reached $689 million.
SYFOVRE demand grew by 17% with plans for a prefilled syringe submission.
EMPAVELI continues to penetrate the market with pivotal trials initiated in additional nephrology indications.
SYFOVRE Market Leadership
SYFOVRE maintained a 60% market share in geographic atrophy with consistent quarter-over-quarter injections.
Financial Strength
Preliminary year-end cash and cash equivalents are approximately $466 million, expected to fund operations to profitability.
Pipeline Progress
Pivotal trials initiated for EMPAVELI in new nephrology indications, supporting expansion and growth.
- SYFOVRE experienced strong patient demand with 17% growth in total injections year-over-year.
- EMPAVELI achieved over 5% market penetration in C3G and primary IC-MPGN.
- Development of OCT-F imaging tool and ongoing Phase 2 study of SYFOVRE + APL-3007 for comprehensive complement activity blocking.
Apellis Pharmaceuticals showcases robust commercial growth and strategic focus in advancing treatments for rare diseases, setting a solid foundation for sustainable value creation.